Meeting
2011 ASCO Annual Meeting
Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials.
Authors
M. Blanco-Codesido
Drug Development Unit, The Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom
M. Blanco-Codesido , A. Brunetto , S. Frentzas , V. Moreno Garcia , D. Papadatos-Pastos , J. V. Pedersen , L. Trani , M. Puglisi , D. Sarker , L. R. Molife , U. Banerji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8564)
Abstract #
8564
Poster Bd #
31A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Biochemotherapy with interleukin-2 for metastatic melanoma: Long-term results in 100 patients.
First Author: David R. Minor
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert
Poster
2012 ASCO Annual Meeting
The role of phase I clinical trials in advanced malignant melanoma: Retrospective analysis of CTEP-sponsored trials 1995-2011.
First Author: Jason John Luke